Tango Therapeutics TNGX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -206.2%+150pp | -178.4%+168pp | -165.9%+156pp | -647.3%-336pp | -355.9%-17.1pp | |
| Net margin | -188.2%+135pp | -162.9%+147pp | -151.1%+133pp | -599.1%-325pp | -322.7%-22.8pp | |
| EBITDA margin | -202.5%+147pp | -174.7%+165pp | -162.3%+154pp | -637.1%-331pp | -349.8%-17.6pp | |
| Free cash flow margin | -250.1%+81.5pp | -224.3%+90.1pp | -220.7%+63.2pp | -613.9%-330pp | -331.7%-3.9pp | |
| Returns | ||||||
| Return on equity | -38.4%+22.9pp | -37.2%+20.3pp | -51.7%-2.9pp | -76.1%-25.5pp | -61.3%-15.9pp | |
| Return on assets | -30.2%+8.7pp | -28.4%+7.8pp | -35.7%-4.1pp | -47%-16.4pp | -38.9%-11.3pp | |
| Return on invested capital | -57.7%+18.7pp | -51.3%+23.4pp | -64%-3.9pp | -87.5%-23.6pp | -76.4%-20.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 27.4×+21.1× | 16.3×+9.3× | 8.9×+0.9× | 4.7×-2.7× | 6.3×-2.0× | |
| Quick ratio | 27.4×+21.1× | 16.3×+9.3× | 8.9×+0.9× | 4.7×-2.7× | 6.3×-2.0× | |
| Cash ratio | 11.2×+9.5× | 5.2×+3.4× | 3.3×+1.8× | 1×-0.2× | 1.7×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.2×+0.1× | 0.3×+0.1× | 0.2×+0.1× | |
| Debt-to-assets | 0.1×-0.1× | 0.1×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $2.73+80.4% | $2.98+63.1% | $1.36-35.7% | $1.22-46.6% | $1.51-38.2% | |
| Valuation | ||||||
| Market capitalization | $2.99B+1,915% | $1.19B+259% | $934.59M+12.1% | $580.99M-37.4% | $148.11M-80.8% | |
| Enterprise value | $2.86B+2,204% | $1.11B+273% | $908.44M+11.3% | $574.16M-37.0% | $124.05M-83.4% | |
| Price / sales | 52.4×+48.8× | 19.1×+11.2× | 14.1×-5.2× | 23.9×+2.1× | 3.6×-17.1× | |
| Price / book | 7.6×+6.7× | 3.4×+1.8× | 5.8×+2.2× | 4.3×+0.6× | 0.9×-2.0× | |
| EV / sales | 50.1×+47.1× | 17.9×+10.8× | 13.7×-5.1× | 23.6×+2.2× | 3×-17.0× | |
| Free cash flow yield | -4.8%+87.0pp | -11.7%+28.1pp | -15.7%-0.9pp | -25.7%-12.7pp | -91.8%-76.0pp | |
| Earnings yield | -3.6%+85.7pp | -8.5%+30.7pp | -10.8%+4.0pp | -25.1%-12.5pp | -89.3%-74.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tango Therapeutics's ratios come from?
- Every ratio is computed from Tango Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.